David C. Griffith

3.8k total citations
62 papers, 2.0k citations indexed

About

David C. Griffith is a scholar working on Pharmacology, Molecular Medicine and Epidemiology. According to data from OpenAlex, David C. Griffith has authored 62 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Pharmacology, 34 papers in Molecular Medicine and 17 papers in Epidemiology. Recurrent topics in David C. Griffith's work include Antibiotics Pharmacokinetics and Efficacy (35 papers), Antibiotic Resistance in Bacteria (34 papers) and HIV/AIDS Research and Interventions (9 papers). David C. Griffith is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (35 papers), Antibiotic Resistance in Bacteria (34 papers) and HIV/AIDS Research and Interventions (9 papers). David C. Griffith collaborates with scholars based in United States, United Kingdom and Australia. David C. Griffith's co-authors include Michael N. Dudley, Olga Lomovskaya, Mojgan Sabet, Ziad Tarazi, Debora Rubio-Aparicio, Dongxu Sun, Ruslan Tsivkovski, Louise A. Kelly‐Hope, Mark A. Miller and Kirk Nelson and has published in prestigious journals such as PEDIATRICS, Journal of Medicinal Chemistry and Antimicrobial Agents and Chemotherapy.

In The Last Decade

David C. Griffith

60 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David C. Griffith United States	22	1.0k	783	542	310	291	62	2.0k
Dimitrios K. Matthaiou Greece	26	1.0k 1.0×	580 0.7×	1.0k 1.9×	299 1.0×	522 1.8×	49	2.6k
M. Montero Spain	26	1.3k 1.3×	668 0.9×	785 1.4×	477 1.5×	508 1.7×	89	2.7k
Ayman Noreddin United States	25	1.1k 1.1×	1.0k 1.3×	984 1.8×	473 1.5×	535 1.8×	73	2.9k
Inga Odenholt Sweden	29	821 0.8×	729 0.9×	838 1.5×	303 1.0×	673 2.3×	73	2.4k
Lütfiye Mülazımoğlu Türkiye	18	1.4k 1.4×	501 0.6×	740 1.4×	307 1.0×	451 1.5×	38	2.5k
Silvia Corcione Italy	25	1.1k 1.1×	714 0.9×	820 1.5×	182 0.6×	717 2.5×	158	2.7k
Karen E. Bowker United Kingdom	25	804 0.8×	888 1.1×	528 1.0×	190 0.6×	420 1.4×	89	1.9k
Elizabeth B. Hirsch United States	21	1.2k 1.2×	658 0.8×	578 1.1×	364 1.2×	238 0.8×	68	2.0k
Stephanie H. Factor United States	21	712 0.7×	295 0.4×	864 1.6×	183 0.6×	456 1.6×	47	2.2k
Shio‐Shin Jean Taiwan	23	858 0.8×	319 0.4×	538 1.0×	239 0.8×	761 2.6×	45	2.1k

Countries citing papers authored by David C. Griffith

Since Specialization

Citations

This map shows the geographic impact of David C. Griffith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David C. Griffith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David C. Griffith more than expected).

Fields of papers citing papers by David C. Griffith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David C. Griffith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David C. Griffith. The network helps show where David C. Griffith may publish in the future.

Co-authorship network of co-authors of David C. Griffith

This figure shows the co-authorship network connecting the top 25 collaborators of David C. Griffith. A scholar is included among the top collaborators of David C. Griffith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David C. Griffith. David C. Griffith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wallis, Steven C., Elizabeth E. Morgan, Michael N. Dudley, et al.. (2023). A phase I, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of the pharmacokinetics, safety, and tolerability of oral ceftibuten in healthy adult subjects. Antimicrobial Agents and Chemotherapy. 68(1). e0109923–e0109923. 1 indexed citations

Reddy, K. Raja, Maxim Totrov, Olga Lomovskaya, et al.. (2022). Broad-spectrum cyclic boronate β-lactamase inhibitors featuring an intramolecular prodrug for oral bioavailability. Bioorganic & Medicinal Chemistry. 62. 116722–116722. 6 indexed citations

Tarazi, Ziad, et al.. (2022). 615. Pharmacodynamics (PD) of the Beta-Lactamase Inhibitor Xeruborbactam When Administered in Combination with Meropenem. Open Forum Infectious Diseases. 9(Supplement_2). 3 indexed citations

Lomovskaya, Olga, Ruslan Tsivkovski, Dongxu Sun, et al.. (2021). QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics. Frontiers in Microbiology. 12. 697180–697180. 34 indexed citations

Fields, Errol L., et al.. (2020). Addressing Health Inequities Exacerbated by COVID-19 Among Youth With HIV: Expanding Our Toolkit. Journal of Adolescent Health. 67(2). 290–295. 31 indexed citations

Bayliss, Mark, et al.. (2019). Development, validation and application of a novel HPLC-MS/MS method for the measurement of minocycline in human plasma and urine. Journal of Pharmaceutical and Biomedical Analysis. 169. 90–98. 17 indexed citations

Bayliss, Mark, et al.. (2019). Challenges in the bioanalysis of tetracyclines: Epimerisation and chelation with metals. Journal of Chromatography B. 1134-1135. 121807–121807. 13 indexed citations

Griffith, David C., et al.. (2019). 190. Patterns of Retention In HIV Care And Factors Associated With Viral Suppression In Youth And Young Adults Age 18-30 With HIV In An Urban Practice. Journal of Adolescent Health. 64(2). S97–S97. 1 indexed citations

Sime, Fekade B., Saurabh Pandey, Suzanne L. Parker, et al.. (2018). Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam. Antimicrobial Agents and Chemotherapy. 62(10). 27 indexed citations

10.

Sabet, Mojgan, Ziad Tarazi, & David C. Griffith. (2018). Activity of Meropenem-Vaborbactam against Pseudomonas aeruginosa and Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model. Antimicrobial Agents and Chemotherapy. 63(1). 17 indexed citations

11.

Ambrose, Paul G., Olga Lomovskaya, David C. Griffith, Michael N. Dudley, & Brian VanScoy. (2017). β-Lactamase inhibitors: what you really need to know. Current Opinion in Pharmacology. 36. 86–93. 22 indexed citations

12.

Jao, Jennifer, Lee Fairlie, David C. Griffith, & Allison L. Agwu. (2016). The Challenge of and Opportunities for Transitioning and Maintaining a Continuum of Care Among Adolescents and Young Adults Living with HIV in Resource Limited Settings. Current Tropical Medicine Reports. 3(4). 149–157. 8 indexed citations

13.

Griffith, David C. & David Adler. (2015). Knowledge of HPV among HIV-Infected and HIV-Uninfected Adolescent Women in South Africa. PubMed. 4(5). 5 indexed citations

14.

Tsivkovskii, Ruslan, Mojgan Sabet, Ziad Tarazi, et al.. (2010). Levofloxacin reduces inflammatory cytokine levels in human bronchial epithelia cells: implications for aerosol MP-376 (levofloxacin solutionfor inhalation) treatment of chronic pulmonary infections. FEMS Immunology & Medical Microbiology. 61(2). 141–146. 40 indexed citations

15.

King, P. A., Diane M. Citron, David C. Griffith, Olga Lomovskaya, & Michael N. Dudley. (2009). Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients. Diagnostic Microbiology and Infectious Disease. 66(2). 181–186. 45 indexed citations

16.

Dudley, Michael N., et al.. (2008). Aerosol antibiotics: considerations in pharmacological and clinical evaluation. Current Opinion in Biotechnology. 19(6). 637–643. 38 indexed citations

17.

Watkins, William J., Lee S. Chong, Aesop Cho, et al.. (2007). Quinazolinone fungal efflux pump inhibitors. Part 3: (N-methyl)piperazine variants and pharmacokinetic optimization. Bioorganic & Medicinal Chemistry Letters. 17(10). 2802–2806. 21 indexed citations

18.

Glinka, Tomasz, Keith Huie, Aesop Cho, et al.. (2003). Relationships between structure, antibacterial activity, serum stability, pharmacokinetics and efficacy in 3-(heteroarylthio)cephems. Discovery of RWJ-333441 (MC-04,546). Bioorganic & Medicinal Chemistry. 11(4). 591–600. 7 indexed citations

19.

Hecker, Scott J., Tomasz Glinka, Aesop Cho, et al.. (2000). Discovery of RWJ-54428 (MC-02,479), a New Cephalosporin Active Against Resistant Gram-positive Bacteria.. The Journal of Antibiotics. 53(11). 1272–1281. 16 indexed citations

20.

Smeltzer, Mark S., J. R. Thomas, Robert A. Skinner, et al.. (1997). Characterization of a rabbit model of staphylococcal osteomyelitis. Journal of Orthopaedic Research®. 15(3). 414–421. 167 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact